Sodium channel protein type 2 subunit alpha (SCN2A) (SCN2A)

Sodium channel protein type 2 subunit alpha, encoded by the SCN2A gene, is a voltage-gated sodium channel (NaV1.2) essential for generating and propagating action potentials in the central nervous system [3, 11]. It is primarily expressed in the axon initial segment of excitatory neurons, making it a critical regulator of neuronal excitability and brain development [3, 15]. Pathogenic variants in SCN2A are associated with a diverse spectrum of neurodevelopmental disorders, including benign familial neonatal-infantile seizures, severe developmental and epileptic encephalopathies (DEE), autism spectrum disorder (ASD), and intellectual disability [7, 16]. The therapeutic approach is highly dependent on the functional consequence of the mutation: gain-of-function variants typically respond to sodium channel blockers like phenytoin or carbamazepine, whereas loss-of-function variants, often seen in ASD, require therapies that avoid further channel inhibition [9, 14]. Precision medicine is critical for this target, as using traditional sodium channel blockers in patients with loss-of-function mutations can paradoxically exacerbate neurological symptoms [10, 14]. Current drug development efforts focus on novel modalities, including antisense oligonucleotides like elsunersen (PRAX-222) and selective small molecules such as relutrigine (PRAX-562) that modulate channel activity or gene expression to restore normal signaling [1, 2]. These advancements emphasize the importance of genotype-phenotype correlation in selecting the appropriate therapeutic intervention for SCN2A-related disorders [3, 15].

Other names

NaV1.2NAC2SCN2A1BFIC3BFIS3BNFISEA9EIEE11HBAHBSCIHBSCII

Voltage-gated sodium channel blockade and modulation of gene expression via antisense oligonucleotides or gene therapy.